Keros Therapeutics, Inc. (KROS) Tops Q2 EPS by 8c

Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q2 EPS of ($1.27), $0.08 better than the analyst estimate of ($1.35).

For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c